LEADER 03511nam1 22004331i 450 001 UON00287249 005 20250319105609.691 100 $a20070126d1955 |0itac50 ba 101 $apol 102 $aPL 105 $a|||| 1|||| 200 1 $aDziela$fAdam Mickiewicz 210 $aWarszawa$cCzytelnik$d1955 215 $a16 v.$d20 cm. 463 1$1001UON00527921$12001 $aˆ1: ‰Wiersze$fAdam Mickiewicz$1210 $aWarszawa$cSpoldzielnia Wydawnicza Czytelnik$d1955$1215 $a680 p.$d21 cm$v01 463 1$1001UON00287262$12001 $aPowiesci poetyckie$fAdam Mickiewicz$1205 $aWarszawa : Czytelnik$b1955$1210 $a290 p.$ctav. ; 20cm$1215 $aInd. op.: Grazyna$dKonrad Wallenrod$dGiaur$dKorybut [Autograf "Grazyny"].$v02 463 1$1001UON00287276$12001 $aUtwory dramatyczne$fAdam Mickiewicz$1205 $aWarszawa : Czytelnik$b1955$1210 $a537 p.$ctav. ; 20cm$1215 $aInd. op.: Dziady.$v03 463 1$1001UON00287280$12001 $aPan Tadeusz$fAdam Mickiewicz$1210 $aWarszawa$cCzytelnik$d1955$1215 $a473 p.$ctav.$d20cm.$v04 463 1$1001UON00287286$12001 $aPisma proza$eczesc 1. : Pisma filomatyczne, estetyczno-krytyczne, opowiadania$fAdam Mickiewicz$1210 $aWarszawa$cCzytelnik$d1955$1215 $a483 p.$ctav.$d20cm.$v05 463 1$1001UON00287288$12001 $aPisma proza. Czesc 1. : Ksiegi Narodu Polskiego i pielgrzymstwa polskiego ; pisma polityczne z lat 1832-1835$fAdam Mickiewicz$1210 $aWarszawa$cCzytelnik$d1955$1215 $a280 p.$ctav.$d20cm.$v06 463 1$1001UON00287291$12001 $aPisma proza. Czesc 3. : Pisma historyczne ; Wyklady lozanskie$fAdam Mickiewicz$1210 $aWarszawa$cCzytelnik$d1955$1215 $a334 p.$ctav.$d20cm.$v07 463 1$1001UON00287293$12001 $aLiteratura Slowianska$eKurs pierwszy polrocze 1. / Adam Mickiewicz ; przel. Leon Ploszewski$1210 $aWarszawa$cCzytelnik$d1955$1215 $a420 p.$ctav.$d20cm.$v08 463 1$1001UON00287296$12001 $aLiteratura Slowianska$eKurs pierwszy polrocze 2. / Adam Mickiewicz ; przel. Leon Ploszewski$1210 $aWarszawa$cCzytelnik$d1955$1215 $a270 p.$ctav.$d20cm.$v09 463 1$1001UON00287299$12001 $aLiteratura Slowianska$eKurs drugi$fAdam Mickiewicz$gprzel. Leon Ploszewski$1210 $aWarszawa$cCzytelnik$d1955$1215 $a500 p.$ctav.$d20cm.$v10 463 1$1001UON00287305$12001 $aLiteratura Slowianska$eKurs trzeci i czwarty$fAdam Mickiewicz$gprzel. Leon Ploszewski$1210 $aWarszawa$cCzytelnik$d1955$1215 $a627 p.$ctav.$d20cm.$v11 463 1$1001UON00287307$12001 $aTrybuna lodow$fAdam Mickiewicz$1210 $aWarszawa$cCzytelnik$d1955$1215 $a483 p.$ctav.$d20cm.$v12 463 1$1001UON00287310$12001 $aPisma rozne$fAdam Mickiewicz$1205 $aWarszawa : Czytelnik$b1955$1210 $a275 p.$ctav. ; 20cm$1215 $aInd. op.: Pisma religijno-filozoficzne$dPisma towianistyczne [et al.]$v13 463 1$1001UON00287311$12001 $aListy$eczesc 1. / Adam Mickiewicz$1210 $aWarszawa$cCzytelnik$d1955$1215 $a639 p.$ctav.$d20cm.$v14 463 1$1001UON00287313$12001 $aListy$eczesc 2. / Adam Mickiewicz$1210 $aWarszawa$cCzytelnik$d1955$1215 $a703 p.$ctav.$d20 cm.$v15 463 1$1001UON00287314$12001 $aListy$eczesc 3. / Adam Mickiewicz$1210 $aWarszawa$cCzytelnik$d1955$1215 $a750 p.$ctav.$d20 cm.$v16 620 $aPL$dWarszawa$3UONL000573 676 $a891.85$cLetteratura polacca$v21 700 1$aMickiewicz$bAdam$3UONV023600$0143464 712 $aCzytelnik$3UONV256601$4650 790 0$aMICIKAIWEIZHI$zMickiewicz, Adam$3UONV023602 801 $aIT$bSOL$c20250321$gRICA 912 $aUON00287249 996 $aDziela$91210057 997 $aUNIOR LEADER 05880nam 2200781Ia 450 001 9910815366903321 005 20200520144314.0 010 $a9781118610732 010 $a1118610733 010 $a9781118610749 010 $a1118610741 010 $a9781299465282 010 $a1299465285 010 $a9781118610756 010 $a111861075X 035 $a(CKB)2550000001019426 035 $a(EBL)1166922 035 $a(OCoLC)850209522 035 $a(SSID)ssj0000855714 035 $a(PQKBManifestationID)11440512 035 $a(PQKBTitleCode)TC0000855714 035 $a(PQKBWorkID)10804846 035 $a(PQKB)10701429 035 $a(MiAaPQ)EBC1166922 035 $a(DLC) 2013014058 035 $a(Au-PeEL)EBL1166922 035 $a(CaPaEBR)ebr10687823 035 $a(CaONFJC)MIL477778 035 $a(PPN)178710350 035 $a(Perlego)1004060 035 $a(EXLCZ)992550000001019426 100 $a20130330d2013 uy 0 101 0 $aeng 135 $aur|n|---||||| 181 $ctxt 182 $cc 183 $acr 200 00$aAdvanced delivery and therapeutic applications of RNAi /$fedited by Kun Cheng, Ram I. Mahato 205 $a2nd ed. 210 $aChichester, West Sussex $cJohn Wiley & Sons Inc.$d2013 215 $a1 online resource (535 p.) 300 $aDescription based upon print version of record. 311 08$a9781119976868 311 08$a1119976863 320 $aIncludes bibliographical references and index. 327 $aAdvanced Delivery and Therapeutic Applications of RNAi; Contents; Preface; Contributors; About the Editors; Part 1: Introduction and Basics of RNAi; 1 Mechanisms and Barriers to RNAi Delivery; 1.1 Introduction; 1.2 Barriers to Systemic RNAi Delivery; 1.3 Rational Design to Improve RNAi Efficacy; 1.4 Chemical Modifications to Enhance siRNA Stability and Reduce Immune Response; 1.5 Cellular Uptake and Intracellular Release of siRNA; 1.6 Combinatorial Targeting for Targeted RNAi Delivery; 1.7 Cell-Specific Aptamer-Functionalized Nanocarriers for RNAi Delivery 327 $a1.8 The Clinical Development and Challenges of siRNAs Therapeutics1.9 Conclusion and Perspectives; References; 2 Analysis of siRNA Delivery Using Various Methodologies; 2.1 Introduction; 2.2 Checkpoints for Analyzing siRNA Delivery; 2.2.1 Circulation Checkpoint; 2.2.2 Organ or Tissue Checkpoint; 2.2.3 Cellular Checkpoint; 2.2.4 RISC Checkpoint; 2.2.5 Target mRNA Knockdown (Indirect Checkpoint); 2.2.6 Protein and Outcome (Indirect Checkpoint); 2.2.7 Safety (Indirect Checkpoint); 2.3 Methods for Analysis of siRNA; 2.3.1 General Considerations; 2.3.2 Hybridization-Based (Non-Imaging) Methods 327 $a2.3.3 Non-Hybridization-Based (Non-Imaging) Methods2.3.4 Imaging-Based (Non-Hybridization) Methods; 2.3.5 Imaging-Based (Hybridization) Methods; 2.4 Case Study for siRNA Delivery Analysis; References; 3 Challenges and Opportunities in Bringing RNAi Technologies from Bench to Bed; 3.1 Introduction; 3.2 RNAi Mediator (siRNA or shRNA); 3.2.1 siRNA; 3.2.2 Vector-derived shRNA; 3.2.3 miRNAs; 3.3 Safety Issues of RNAi Mediators; 3.3.1 Immune Stimulation; 3.3.2 RNAi Overexpression; 3.4 Efficacy of RNAi Mediators; 3.4.1 Therapeutic Response; 3.5 RNAi Mediators in Clinical Trials; 3.6 Conclusion 327 $aReferences4 Nonclinical Safety Assessments and Clinical Pharmacokinetics for Oligonucleotide Therapeutics: A Regulatory Perspective; 4.1 Introduction; 4.2 Unique Properties of Oligonucleotide-based Therapeutics; 4.3 Regulation of Oligonucleotide-Based Therapeutics; 4.3.1 Submission to the FDA; 4.3.2 Review Process for Non-clinical Studies; 4.3.3 Regulatory Issues; 4.3.4 Clinical Pharmacokinetics; 4.4 Conclusion; Disclaimer; Appendix; References; 5 Role of Promoters and MicroRNA Backbone for Efficient Gene Silencing; 5.1 Introduction; 5.2 Promoters for shRNA Expression 327 $a5.2.1 Constitutive Promoters5.2.2 Inducible Promoters; 5.2.3 Site Specific Promoters; 5.3 miRNA-based shRNAs; 5.3.1 miRNA-based shRNA Enhances Gene Silencing; 5.3.2 miRNA-based shRNA Reduces Toxicities; 5.3.3 Application of miRNA-based shRNA for Combination Gene Therapy; 5.4 Concluding Remarks; References; Part 2: RNAi Delivery Strategies; 6 Bioconjugation of siRNA for Site-specific Delivery; 6.1 Introduction; 6.2 Conjugation Strategy; 6.2.1 RNA Chemical Modification; 6.2.2 Site of Conjugation; 6.2.3 Conjugation Chemistry; 6.3 Bioconjugates for Site-specific Delivery 327 $a6.3.1 Antibody-siRNA Bioconjugates 330 $a"Commonly used by researchers to develop technologies for modifying and studying genetic process, RNA interference (RNAi) has many potential uses in medicine, biotechnology, and functional genomics. This book covers all essential aspects involved in the development of RNAi therapeutics, providing detailed guidance on the challenges and opportunities of bringing RNAi technologies from bench to clinic. It explores the design and mechanism of RNAi molecules, delivery strategies, and therapeutic applications in various diseases. Preclinical, regulatory, market, and intellectual aspects of RNAi technologies are also covered"--$cProvided by publisher. 330 $a"All of the essential aspects of developing RNAi therapeutics from bench to clinic presented in a single volume"--$cProvided by publisher. 606 $aRNA$xTherapeutic use 606 $aSmall interfering RNA$xTherapeutic use 615 0$aRNA$xTherapeutic use. 615 0$aSmall interfering RNA$xTherapeutic use. 676 $a572.8/8 686 $aSCI013040$2bisacsh 701 $aCheng$b Kun$0923418 701 $aMahato$b Ram I$0940187 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910815366903321 996 $aAdvanced delivery and therapeutic applications of RNAi$94001126 997 $aUNINA LEADER 01574nam0 2200289 4500 001 000038315 005 20251008103426.0 010 $a9780226826202 100 $a20251008d2024----km-y0itay50------ba 101 0 $aeng 102 $aUK 105 $aa-------001yy 200 1 $aEconomy and interest$ea new presentation of the fundamental problems related to the economic role of the rate of interest and their solutions$fMaurice Allais$gtranslated by John Stephen Daly$gpreface to the American edition by Bertrand Munier 210 $aChicago$cThe University of Chicago Press$d2024$aLondon 215 $aXL, 820 p.$d24 cm. 327 0 $aEconomia e interesse è la prima traduzione in inglese dell'opera fondamentale di Allais, le cui scoperte hanno anticipato di decenni le formulazioni accettate da altri famosi economisti. Pochi studiosi hanno ampliato i confini della modellizzazione conomica più dell'economista francese Maurice Allais i cui contributi gli sono valsi il Premio Nobel e hanno suscitato paragoni con le opere di Paul Samuelson e persino di alcuni moderni economisti comportamentali matematici. 500 10$aEconomy and interest$94404960 610 1 $aEconomia finanziaria$ainteressi$aTasso 676 $a332.8$v23$9Economia finanziaria. Interesse 700 1$aAllais,$bMaurice$0121556 702 1$aMunier,$bBertrand$4080 702 1$aDaly,$bJohn Stephen$4730 801 0$aIT$bUNIPARTHENOPE$c20251008$gRICA$2UNIMARC 912 $a000038315 951 $a332-E/61$b50189$cNAVA1$d2025 996 $aEconomy and interest$94404960 997 $aUNIPARTHENOPE